Free Trial
NASDAQ:MLYS

Mineralys Therapeutics (MLYS) Stock Price, News & Analysis

Mineralys Therapeutics logo
$15.00 +0.52 (+3.55%)
As of 02:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Mineralys Therapeutics Stock (NASDAQ:MLYS)

Key Stats

Today's Range
$14.07
$15.17
50-Day Range
$13.45
$16.66
52-Week Range
$8.24
$18.38
Volume
214,400 shs
Average Volume
554,782 shs
Market Capitalization
$978.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.25
Consensus Rating
Moderate Buy

Company Overview

Mineralys Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

MLYS MarketRank™: 

Mineralys Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 608th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Mineralys Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Mineralys Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Mineralys Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($4.23) to ($4.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mineralys Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mineralys Therapeutics is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Mineralys Therapeutics has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Mineralys Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.89% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 24.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Mineralys Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Mineralys Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.89% of the float of Mineralys Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Mineralys Therapeutics has a short interest ratio ("days to cover") of 9.2.
  • Change versus previous month

    Short interest in Mineralys Therapeutics has recently increased by 24.31%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Mineralys Therapeutics has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Mineralys Therapeutics this week, compared to 5 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $338,934.00 in company stock.

  • Percentage Held by Insiders

    33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Mineralys Therapeutics' insider trading history.
Receive MLYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLYS Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
See More Headlines

MLYS Stock Analysis - Frequently Asked Questions

Mineralys Therapeutics' stock was trading at $12.31 at the start of the year. Since then, MLYS stock has increased by 21.1% and is now trading at $14.9070.

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) issued its quarterly earnings results on Monday, May, 12th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23.
Read the conference call transcript
.

Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering (IPO) on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share.

Mineralys Therapeutics' top institutional investors include Swedbank AB (0.59%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Ra Capital Management, LP, Hbm Healthcare Investments (Ca, Jon Congleton, Adam Scott Levy and David Malcom Rodman.
View institutional ownership trends
.

Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mineralys Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/12/2025
Today
7/14/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLYS
CIK
1933414
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

High Price Target
$48.00
Low Price Target
$15.00
Potential Upside/Downside
+116.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$177.81 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-71.15%
Return on Assets
-65.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.48
Quick Ratio
26.48

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.84 per share
Price / Book
3.88

Miscellaneous

Outstanding Shares
65,180,000
Free Float
43,511,000
Market Cap
$971.64 million
Optionable
Optionable
Beta
-0.30
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:MLYS) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners